文献速递乳腺癌

卡培他滨辅助治疗早期乳腺癌:一项随机试验的15年总生存结果

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
PubMed 文献 · J Clin Oncol · 2022-01-12

FinXX随机多中心开放标签试验纳入1500例腋窝淋巴结阳性或高危淋巴结阴性早期乳腺癌患者,比较TX-CEX方案与T-CEF方案辅助化疗。中位随访约15.3年,TX-CEX组总生存优于T-CEF组(HR 0.81,95%CI 0.66-0.99,P=0.037),15年生存率分别为77.6%和73.3%。

要点

  • TX-CEX组15年总生存率77.6%,T-CEF组73.3%(HR 0.81,95%CI 0.66-0.99,P=0.037)。
  • 中位随访:TX-CEX组存活患者15.3年,T-CEF组15.4年。
  • 探索性亚组中雌激素受体阴性及三阴性乳腺癌患者TX-CEX组似有更长生存。

核心结论

  • 在含多西他赛、表柔比星和环磷酰胺的化疗方案中加入卡培他滨延长了早期乳腺癌患者的总生存。

研究设计与样本

  • FinXX为随机、开放标签、多中心试验,评估将卡培他滨整合入含紫杉类和蒽环类的辅助化疗方案。
  • 2004年1月27日至2007年5月29日共入组1500例腋窝淋巴结阳性或高危淋巴结阴性早期乳腺癌患者。
  • 患者随机分配至TX-CEX组(753例,多西他赛+卡培他滨3周期后环磷酰胺+表柔比星+卡培他滨3周期)或T-CEF组(747例,多西他赛3周期后环磷酰胺+表柔比星+氟尿嘧啶3周期)。
  • 基于约15年随访按方案预设分析总生存,数据截止2020年12月31日。

主要发现

  • TX-CEX组总生存优于T-CEF组(HR 0.81;95%CI 0.66-0.99;P=0.037)。
  • 15年生存率TX-CEX组为77.6%,T-CEF组为73.3%。
  • 存活患者中位随访时间TX-CEX组为15.3年(四分位距14.5-16.1年),T-CEF组为15.4年(四分位距14.8-16.0年)。
  • 探索性亚组分析中,雌激素受体阴性乳腺癌和三阴性乳腺癌患者接受TX-CEX治疗较T-CEF有更长生存趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy regimen containing a taxane and an anthracycline for the treatment of early breast cancer. Between January 27, 2004, and May 29, 2007, 1,500 patients with axillary node-positive or high-risk node-negative early breast cancer were accrued. The patients were randomly allocated to either TX-CEX, consisting of three cycles of docetaxel (T) plus capecitabine (X) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX, 753 patients), or to T-CEF, consisting of three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF, 747 patients). We performed a protocol-scheduled analysis of overall survival on the basis of approximately 15-year follow-up of the patients. RESULTS: The data collection was locked on December 31, 2020. By this date, the median follow-up time of the patients alive was 15.3 years (interquartile range, 14.5-16.1 years) in the TX-CEX group and 15.4 years (interquartile range, 14.8-16.0 years) in the T-CEF group. Patients assigned to TX-CEX survived longer than those assigned to T-CEF (hazard ratio 0.81; 95% CI, 0.66 to 0.99; P = .037). The 15-year survival rate was 77.6% in the TX-CEX group and 73.3% in the T-CEF group. In exploratory subgroup analyses, patients with estrogen receptor-negative cancer and those with triple-negative cancer treated with TX-CEX tended to live longer than those treated with T-CEF. CONCLUSION: Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022. PMID: 35020465. doi:10.1200/JCO.21.02054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。